Zepbound, Wegovy, Ozempic and alcohol: can you drink?

The Zepbound label doesn’t tell you to avoid alcohol, but it doesn’t say drinking is fine either: Eli Lilly says it has not studied tirzepatide with alcohol use and can’t recommend for or against it. The same gap applies to Wegovy and Ozempic, so the practical limits come from label warnings that drinking can add to, mainly pancreatitis, low blood sugar and dehydration, and from an honest talk with your prescriber about how much you drink.

Can you drink on Zepbound? What Lilly says

Zepbound is tirzepatide for weight loss, and its prescribing information (rev. 08/2026) has no section on drinking alcohol. Lilly’s medical information page answers the question directly (Lilly Medical, read Oct 27, 2026):

• Lilly has not evaluated tirzepatide with alcohol use or for alcohol use disorder, and cannot recommend whether to use it in someone who drinks or has alcohol use disorder.
• Your clinician can weigh your medical history, other medicines and other factors in a treatment plan.
• Lilly’s tirzepatide trials excluded people with a history of alcohol abuse.
• Tirzepatide is not indicated to treat alcohol use disorder, and Lilly has no plans to study it for that use. Lilly says it did not sponsor the outside studies that exist and can’t vouch for them.

One point often confuses people. The multi-dose KwikPen and multi-dose vial contain benzyl alcohol as a preservative. Lilly says benzyl alcohol does not contain ethanol, the alcohol in drinks, and does not turn into it in the body.

Mounjaro, the tirzepatide brand for type 2 diabetes, has the same gap: its label (rev. 08/2026) doesn’t address drinking.

Wegovy and alcohol, and Ozempic and alcohol

The Wegovy label (rev. 06/2026) and the Ozempic label (rev. 05/2026) don’t address drinking alcohol either. Both are semaglutide. Wegovy is approved for weight loss and Ozempic for type 2 diabetes, and they share the warnings below.

Safety: what the labels warn about

The boxed warning comes first

Every one of these labels carries a boxed warning, the FDA’s strongest, for thyroid C-cell tumors. Semaglutide caused them in mice and rats, and tirzepatide in rats; whether the drugs do the same in people is unknown. They are not for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your clinician about a neck lump, trouble swallowing, shortness of breath or lasting hoarseness. Alcohol has no known link to this warning, but it is the first thing to know about any of these drugs.

Pancreatitis and gallbladder disease

All 4 labels warn that acute pancreatitis, including fatal cases, has been seen with GLP-1 drugs. The sign to know is persistent or severe stomach pain, sometimes spreading to the back, with or without nausea or vomiting. If pancreatitis is suspected, the labels say to stop the drug and get care (Zepbound label section 5.5; Wegovy label section 5.2).

Alcohol matters here because gallstones and heavy alcohol use are the most common causes of both acute and chronic pancreatitis (NIDDK). The GLP-1 labels also warn about gallbladder disease: in Zepbound’s weight trials, gallstones were reported in 1.1% of people on Zepbound vs 1% on placebo, and gallbladder inflammation in 0.7% vs 0.2%.

Low blood sugar

Zepbound lowers blood sugar and can cause hypoglycemia. In a trial of adults with type 2 diabetes, 4.2% on Zepbound had blood sugar below 54 mg/dL vs 1.3% on placebo, rising to 10.3% among those also taking a sulfonylurea. In adults without diabetes, the trial recorded it in 0.3% vs none on placebo (Zepbound label sections 5.7 and 6.1).

For people with diabetes, the NIDDK says drinking too much alcohol without enough food makes it harder for the body to keep blood sugar steady, and can hide the first symptoms of a low. Its advice is to eat some food when you drink (NIDDK). If you take insulin or a sulfonylurea with a GLP-1, ask your clinician how alcohol fits in.

Dehydration and kidney injury

The labels warn about acute kidney injury, mostly in people whose nausea, vomiting or diarrhea left them dehydrated. If a night of drinking leaves you vomiting or unable to keep fluids down, that adds to the same risk. Call your clinician if you can’t keep fluids down.

Our GLP-1 side effects guide covers the full list, including the stomach side effects that are most common while doses rise.

What trials show about GLP-1s and drinking less

There have been widespread reports, many on social media, of people drinking less without trying while on GLP-1s (Bremmer and Hendershot, 2024), and researchers are now testing whether the drugs reduce drinking. The trials so far are small and short:

Scroll sideways to see the full table

These results are early. The semaglutide doses were lower than the weight-loss doses, the groups were small, and none of the drugs is approved to treat alcohol use disorder. Don’t count on a GLP-1 to manage drinking; if cutting back is hard, raise it with your clinician as its own problem.

Practical limits if you drink

No label sets a limit, so these are general guides:

• Know what a drink is. In the US, a standard drink holds 14 grams of pure alcohol (NIAAA, updated Jan 2026).
• Stay under the heavy-drinking line. NIAAA defines heavy drinking as 4 or more drinks on any day or 8 or more a week for women, and 5 or more on any day or 15 or more a week for men. Binge drinking, 4 or more drinks for women or 5 or more for men in about 2 hours, also counts as alcohol misuse.
• Remember that less is safer. NIAAA says harms may come with any amount of drinking and rise as the amount goes up, and that people taking medicines that interact with alcohol or with certain medical conditions should avoid it completely.
• Eat when you drink, especially if you take insulin or a sulfonylurea.
• Tell your prescriber how much you drink, and about any past pancreatitis or gallstones, before you start or raise your dose.

If you are still choosing a program, our list of programs that prescribe Zepbound orders the ones we list by our published rating method, and each requires a clinician consult where you can ask these questions.

The bottom line

Zepbound, Mounjaro, Wegovy and Ozempic labels don’t ban alcohol, and Lilly says it hasn’t studied drinking with tirzepatide. The risks to plan around are the labels’ own warnings: pancreatitis, where heavy drinking is a leading cause; low blood sugar, especially with insulin or a sulfonylurea; and dehydration when side effects or a hangover keep fluids down. Early trials suggest semaglutide may cut some drinking measures, but GLP-1s are not a treatment for alcohol use disorder. If you drink, keep it light, eat with it, and tell your prescriber how much.